Abstract:Objective:?To investigate the efficacy of dorsal root ganglion (DRG) injection of platelet-rich plasma (PRP) in improving postherpetic neuralgia (PHN) and to explore its mechanism using a metabolomics approach. Methods:?Forty patients with thoracolumbar PHN were randomly divided into a control group (pregabalin) and a PRP group (pregabalin combined with DRG injection of PRP). The two groups were compared regarding numerical rating scale (NRS) for pain, sleep quality, medication dosage, and adverse reactions. Non-targeted metabolomics was employed to screen for differential metabolites, and metabolic enrichment analysis was performed to identify potentially regulated biological pathways. Results:?A total of 38 patients completed the clinical study (18 in the PRP group, 20 in the control group). After treatment, the PRP group demonstrated superior outcomes compared to the control group in terms of NRS reduction, sleep improvement, and the 28-day pregabalin dose reduction (P < 0.05). The incidence of somnolence was lower in the PRP group (P < 0.05), with no significant differences in other adverse reactions. Metabolomics analysis included 18 samples (8 from the PRP group, 10 from the control group). Differential metabolites, including benzoic acid and β-arginine, were identified and were primarily enriched in the phenylalanine, tyrosine, tryptophan, and glutathione metabolic pathways. Conclusion:?DRG injection of PRP can effectively alleviate PHN, improve sleep, and reduce medication dosage and somnolence. The mechanism may be associated with the regulation of oxidative stress, inflammatory responses, and amino acid metabolic pathways.